1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant:

The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant:

  1. Calliope
    Neuropharmacology 71 (2013):130-140. http://dx.doi.org/10.1016/j.neuropharm.2013.04.003

    S.M. Aarde, P.K. Huang, K.M. Creehan, T.J. Dickerson, M.A. Taffe.

    Abstract
    Recreational use of the cathinone derivative 3,4 methylenedioxypyrovalerone (MDPV; “bath salts”) has increased worldwide in past years, accompanied by accounts of health and legal problems in the popular media and efforts to criminalize possession in numerous jurisdictions. Minimal information exists on the effects of MDPV in laboratory models. This study determined the effects of MDPV, alongside those of the better studied stimulant D-methamphetamine (METH), using rodent models of intravenous self administration (IVSA), thermoregulation and locomotor activity. Male Wistar rats were trained to self administer MDPV or METH (0.05 mg/kg/infusion, i.v.) or were prepared with radiotelemetry implants for the assessment of body temperature and activity responses to MDPV or METH (0 5.6 mg/kg s.c.). METH and MDPV were consistently self administered within 10 training sessions (mg/kg/h; METH Mean ¼ 0.4 and Max ¼ 1.15; MDPV Mean ¼ 0.9 and Max ¼ 5.8). Dose substitution studies demonstrated that behavior was sensitive to dose for both drugs, but MDPV (0.01 0.50 mg/kg/inf) showed greater potency and efficacy than METH (0.1 0.25 mg/kg/inf). In addition, both MDPV and METH increased locomotor activity at lower doses (0.5 1.0 mg/kg, s.c.) and transiently decreased activity at the highest dose (5.6 mg/kg, s.c.). Body temperature increased monotonically with increasing doses of METH but MDPV had a negligible effect on temperature. Stereotypy was associated with relatively high self administered cumulative doses of MDPV (w1.5 mg/kg/h) as well as with non contingent MDPV administration wherein the intensity and duration of stereotypy increased as MDPV dose increased. Thus, MDPV poses a substantial threat for compulsive use that is potentially greater than that for METH.